^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Yidafan (ivonescimab)

i
Other names: AK112, AK 112, AK-112, SMT112, SMT-112, SMT 112
Company:
Akesobio, Summit Therapeutics
Drug class:
PD1 inhibitor, VEGF inhibitor
Related drugs:
4d
New P2 trial • Checkpoint inhibition
|
Anniko (penpulimab-kcqx) • Meiyouheng (becotatug vedotin) • Yidafan (ivonescimab) • becotarug (JMT101)
6d
Observational Study of Objective Response Rate to Ivonescimab Combined with Chemotherapy in Patients with Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma (ChiCTR2600117410)
P=N/A, N=20, Not yet recruiting, Zhujiang Hospital of Southern Medical University; Zhujiang Hospital of Southern Medical University
New trial
|
Yidafan (ivonescimab)
6d
New trial
|
carboplatin • gemcitabine • albumin-bound paclitaxel • Yidafan (ivonescimab)
6d
Prospective, Single-Center, Single-Arm Clinical Study of Ivosidenib (AK112) Combined with Chemotherapy for Neoadjuvant Treatment of Locally Advanced Oral Squamous Cell Carcinoma (ChiCTR2600117076)
P4, N=15, Not yet recruiting, The first affiliated hostipal of nanchang university; The first affiliated hostipal of nanchang university
New P4 trial
|
carboplatin • paclitaxel • docetaxel • pemetrexed • Tibsovo (ivosidenib) • Yidafan (ivonescimab)
6d
New P4 trial
|
Yidafan (ivonescimab)
6d
A Study of Ivonescimab Plus Neoadjuvant Chemotherapy Followed by Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer (ChiCTR2600115927)
P2, N=42, Not yet recruiting, Women’s Hospital, Zhejiang University School of Medicine; Women’s Hospital, Zhejiang University School of Medicine
New P2 trial
|
PD-L1 (Programmed death ligand 1)
|
cisplatin • paclitaxel • Yidafan (ivonescimab)
6d
A Single-Arm, Multicenter Clinical Study of Eribulin Mesylate in Combination with Ivonescimab as First-Line Treatment for Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (ChiCTR2600117652)
P2, N=50, Not yet recruiting, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University; Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative
|
Halaven (eribulin mesylate) • Yidafan (ivonescimab)
9d
New P2 trial
|
oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • Yidafan (ivonescimab)
10d
Enrollment open
|
carboplatin • etoposide IV • Yidafan (ivonescimab)
14d
New P1 trial
|
CD4 (CD4 Molecule)
|
irinotecan • leucovorin calcium • Yidafan (ivonescimab) • fluorouracil topical • muzastotug (ADG126)
15d
New P2 trial • Mismatch repair • pMMR
|
BRAF (B-raf proto-oncogene)
|
BRAF wild-type
|
Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • Yidafan (ivonescimab)
15d
New trial
|
Yidafan (ivonescimab)